For the quarter ending 2025-09-30, ACUT had -$16,950 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -399,897 | -841,811 |
| Depreciation | 0 | 418 |
| Share-based compensation | 23,674 | 41,348 |
| Expenses settled in stock | 0 | 79,000 |
| Prepaid expenses | -24,414 | -56,567 |
| Accounts payable | 63,266 | 55,310 |
| Related party payable | -311,525 | 350,769 |
| Accrued expenses | -4,063 | -10,216 |
| Net cash used in (provided by) operating activities | -604,131 | -268,615 |
| Advances from related party | 610,000 | 347,000 |
| Payments on note payable | 22,819 | 52,090 |
| Net cash used in (provided by) financing activities | 587,181 | 294,910 |
| (decrease) increase in cash | -16,950 | 26,295 |
| Cash and cash equivalents at beginning of period | 5,046 | - |
| Cash and cash equivalents at end of period | 14,391 | - |
Accustem Sciences Inc. (ACUT)
Accustem Sciences Inc. (ACUT)